En vivo
Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma LetterCellSingle-cell mapping of regulatory DNA-protein interactionsCellPlasma signals of lung tumor promotion for molecular cancer preventionCellDeep learning of functional perturbations from condensate morphologyFierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from expertsLonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter10x Genomics Blog10x Genomics Stock On Fire: Up 41% With 8-Day Winning Streak - TrefisLabiotechEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech mediaLonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma PostEli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSNThermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo FinanceeLifeThe NTR/prodrug revolution: Tools for controlling cell loss and regeneration
BioWorld 15 abr 2026

Ensem Therapeutics divulges new KRAS mutant inhibitors

Ensem Therapeutics divulges new KRAS mutant inhibitors

Original
Contenido no disponible. Consulta la fuente original.